Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer.

This analysis showed that AR nuclear localisation following CCG1423 treatment, singly or in combination with enzalutamide, was significantly decreased ( p < 0.01 for CCG1423 and p < 0.05 for the combination) ( Figure 3 B), while cytoplasmic levels were decreased but did not reach statistical significance ( Figure 3 C).

also in 111,027 other papers